Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Karyopharm Therapeutics (KPTI) Research & Development (2016 - 2025)

Karyopharm Therapeutics (KPTI) has disclosed Research & Development for 12 consecutive years, with $33.3 million as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Research & Development fell 15.44% year-over-year to $33.3 million, compared with a TTM value of $143.2 million through Dec 2024, up 3.23%, and an annual FY2025 reading of $125.6 million, down 12.3% over the prior year.
  • Research & Development was $33.3 million for Q4 2024 at Karyopharm Therapeutics, down from $36.1 million in the prior quarter.
  • Across five years, Research & Development topped out at $45.8 million in Q3 2021 and bottomed at $30.9 million in Q4 2022.
  • Average Research & Development over 5 years is $37.1 million, with a median of $36.6 million recorded in 2020.
  • The sharpest move saw Research & Development surged 60.63% in 2020, then plummeted 31.54% in 2022.
  • Year by year, Research & Development stood at $37.2 million in 2020, then grew by 18.34% to $44.0 million in 2021, then fell by 29.7% to $30.9 million in 2022, then rose by 27.31% to $39.4 million in 2023, then fell by 15.44% to $33.3 million in 2024.
  • Business Quant data shows Research & Development for KPTI at $33.3 million in Q4 2024, $36.1 million in Q3 2024, and $38.4 million in Q2 2024.